Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.54 |
| ▸ | DPP4 | P27487 | 5/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850058 | 0.92 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29376792 | 0.92 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL8592150 | 0.90 | DPP8 (0.47) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL8497101 | 0.90 | DPP7 (0.57) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL8592155 | 0.90 | DPP8 (0.47) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30555003 | 0.89 | DPP7 (0.55) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30517415 | 0.89 | DPP7 (0.55) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL5532139 | 0.87 | NOD1 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL17696520 | 0.87 | NOD1 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30833260 | 0.87 | DPP7 (0.57) | DPP7DPP9DPP8DPP4SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-20240417436-A1 | CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-12-19 | — | — | US | disclosed |
| US-20240400614-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-12-05 | — | — | US | disclosed |
| US-20240376170-A1 | CONDITIONALLY ACTIVATED PROTEINS AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| WO-2024150172-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024150174-A1 | CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-20240132563-A1 | BIFUNCTIONAL CYTOKINE COMPOSITIONS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | PDCD1LG2, PDCD1, IL2 | DPP7 2831/4885DPP9 3115/4885DPP8 2896/4885 |
| US-20240417436-A1 | CONDITIONALLY ACTIVATED IMMUNOCYTOKINES AND METHODS OF USE | IL2, PDCD1LG2, CD274 | DPP7 861/4885DPP9 1534/4885DPP8 877/4885 |
| US-20240376170-A1 | CONDITIONALLY ACTIVATED PROTEINS AND METHODS OF USE | SPPL2A, IL2, CPB2 | DPP7 264/4885DPP9 1008/4885DPP8 358/4885 |
| US-20240400614-A1 | CLEAVABLE PEPTIDES AND METHODS OF USE THEREOF | DNPEP, TMPRSS15, CPB1 | DPP7 121/4885DPP9 126/4885DPP8 109/4885 |
| US-20240132563-A1 | BIFUNCTIONAL CYTOKINE COMPOSITIONS | IL2, IL17A, IL2RA | DPP7 651/4885DPP9 2821/4885DPP8 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.